America’s Twice-Weekly Plasma Donors Supply the World’s Medicines

An estimated 215,000 Americans walk into a plasma donation center each day, and a thin slice of them now go twice a week for rent and gas. The Food and Drug Administration allows that pace, 104 visits a year, with 48 hours between sticks. The yellow protein-rich fluid they sell is the raw material for immunoglobulin and hemophilia drugs that other countries do not collect in volume.

Quentin Watts, 32, is one of those regulars. After a seasonal UPS driving job failed to turn permanent in January 2026, he lost a house near his son’s school in southwest Minneapolis and started lining up at 7 a.m. The first-month rate was $100 a visit. Then it dropped to $40.

The 7 a.m. Line Is a Global Supply Chain

Watts had heard about plasma donation from a former colleague, then got hit with center ads the moment he searched. He is needle-shy. Some mornings he sat in the parking lot for 45 minutes before walking in. He picked the closest clinic so someone could fetch him if a stick went wrong. “I was super wary about it,” he said. The new-donor money was too good to refuse.

Plasma is the liquid that makes up a little more than half of blood. A machine pulls blood from one arm, spins off that yellow fraction, and returns red cells and platelets with saline. A first visit often runs about two hours. Repeat visits are usually about one hour. Blood volume typically comes back within 48 hours if the donor drinks water, which is why U.S. source-plasma rules let people return so fast.

Centers pay on the spot with a prepaid debit card. No car is required, unlike delivery gigs. You must be at least 18 and weigh at least 110 pounds, then pass protein and hematocrit checks. Fail those and you are “deferred,” industry language for sent home unpaid. Watts was once turned away for a pimple on his arm.

THE U.S. PLASMA LEDGER

• Daily traffic: An estimated 215,000 Americans visit a collection center each day, most of them men, who tend to carry more body iron.
• The network: The United States had 1,247 plasma centers as of December 2025, per Peter Jaworski, a Georgetown University ethics professor who tracks collections.
• The 2025 haul: Those centers collected 62.5 million liters, a record in his tally.
• The legal ceiling: The FDA cap is twice in seven days, 48 hours apart, or 104 times a year, with no separate annual visit limit in the federal math.

Fewer than 1% of donors hit that ceiling. The average pace is about 14 to 17 times a year, a rate Jaworski says no serious person will call unsafe. The people who do come twice a week are a smaller labor pool, and they are the ones the global medicine trade now leans on.

America Supplies 68% of Plasma for Medicines

The United States has about 5% of the world’s people and supplies 68% of the plasma used to manufacture lifesaving medicines, Jaworski said in a March 2026 Georgetown interview. High-income countries that ban payment still rely on plasma taken from U.S. donors. HHS figures he cites say it takes 130 plasma donations to treat one person with an immunodeficiency for a year.

America with just 5% of the global population provides 68% of the plasma used to manufacture lifesaving medicines for the whole world. That includes the high-income countries that ban payment. All of them rely on plasma donated in the U.S.

Peter Jaworski, professor of ethics, Georgetown University

Denmark has three collection centers. Italy has 13. France, which bans compensation, came up 1.5 million liters short of its needs in 2024, according to his data. “Not one of them can figure out a way to collect enough plasma,” he said. “You either pay people directly, allowing it within your country, or you pay Americans, but you’re paying donors.”

That is the second shift hiding inside the Minneapolis parking lot. Watts is covering a rent hole. The bag on the machine is covering hospital formularies in countries that tell their own citizens the ethical course is a cookie and a glass of milk.

What Donors Take Home After the Needle

BioLife Plasma Services, a Takeda network with more than 230 U.S. centers, still greets visitors with a banner that new donors get up to $800, based on center location, with terms attached. The asterisk is doing a lot of work. Hitting the headline figure means coming twice a week through a new-donor window. After that, posted rates often slide. Watts went from $100 to $40. Online donor groups track weeks when the card loads $40 to $50.

Pay can also move with body weight, because heavier donors can give more volume per session. Jose Covarrubias, a 37-year-old youth counselor in Orange County, California, said the human material is valuable and the check is not. Brad, a 31-year-old truck driver in Sand Springs, Oklahoma, called $60 a visit scraps. Jaworski’s unit math cuts the other way. He puts average donor pay at $60 to $70 and collector pretax profit at $15 to $20 per liter. In 2025, he tallied $4.7 billion in U.S. donor fees against $4.5 to $5 billion in company pretax profits on medicines made from U.S. plasma.

WHAT A VISIT AND A YEAR PAY

CSL Limited posted $15.6 billion in revenue for the year ended June 30, 2025, with CSL Behring, its plasma-medicine arm, at $11.2 billion. Immunoglobulin sales were $6.064 billion, up 7%. In August 2025 the company closed 22 underperforming U.S. centers, 7% of CSL Plasma’s American footprint, and said collection costs, including donor pay and labor, kept falling. Donors who watch the app already knew the second half of that sentence.

The money is also faster than most gig work. It loads a debit card before a paycheck clears, and faster than a sportsbook would settle a bet. That speed is why the chair sits next to payday lending in the household budget, and why people who would never call themselves medical volunteers still keep the 7 a.m. slot.

A New Center Cuts Payday Borrowing

A 2024 paper in The Review of Financial Studies by John M. Dooley of Washington University in St. Louis and Emily A. Gallagher of the University of Colorado Boulder tracked what happens after a center opens. Sellers tend to be young, low-income, and short on ordinary credit. Among borrowers under 35, demand for payday loans falls by over 13%. Foot traffic at nearby stores rises by over 4%.

In a related briefing of the same work, payday transactions among those young adults dropped 18% within three years, close to the 16% drop tied to a $1 rise in the minimum wage. Gallagher has said centers that used to hide in inner-city blocks now open in strip malls beside grocery stores. Two national surveys found 64% of donors giving to cover day-to-day essentials and emergencies, and 19% for nonessential spending. A CSL Plasma survey put 20% of donors as unemployed.

Frey Chu, 31, a Long Beach website entrepreneur, built Discover Plasma, a crowdsourced pay tracker, after his sister and friends started donating in college. He counts nearly 7,000 U.S. subscribers. “The majority of my friends who donate plasma are just trying to get food money,” Chu said. The database exists because posted rates are not posted in a way a donor can trust until they are already in the lobby.

Gallagher’s warning sits beside the payday result. Without clear long-term health prices, she said, people “might be selling their plasma too cheaply.” The neighborhood gets fewer high-interest loans. The donor still has to price a body with incomplete information.

The Safety Study Has Not Enrolled

Watts does not pretend the hour is easy. “I don’t want to sugarcoat it,” he said. “It hurts a bit.” Centers tell donors not to close their eyes, because fainting is a known risk, so he stares at the ceiling and squeezes. After one needle shifted, red cells went into the muscle. His arm swelled for four or five days, and he was barred from donating for two weeks, which meant no card load.

Kevin, 41, in Las Vegas, has made nearly $30,000 over several years at twice a week. He also describes puncture scars that clinicians now mistake for drug marks, and a session where a bad hookup cost him one to one-and-a-half units of blood. He reports chronic fatigue he did not have before. Russ Darbon, 61, a St. Louis steel mill worker, says he has had no trouble and likes the routine blood-pressure and iron checks. “Maybe by accident, it makes me take care of my health more,” he said.

CSL Plasma’s own FAQ warns that frequent donation may raise the risk of depleted immunoglobulin, which can weaken the fight against infection. Grifols, which runs a large global center network, says plasmapheresis “may temporarily affect the immune system but does not pose any significant or long-term health risks.” Veronica Hoad, a public health specialist at Australian Red Cross Lifeblood, has put the research gap in plainer terms: there is not conclusive evidence, in part because high-grade long-term studies are missing. Gallagher adds a selection problem. People who feel worse often stop, so the remaining twice-weekly pool looks healthier than the full group who ever tried.

The industry’s answer is a study that has not yet taken donors. The Plasma Protein Therapeutics Association is sponsoring the Cohort of Repeat Donor Experiences, or CORE, listed as NCT07543965, with Westat as the research shop. The listing still read as not yet enrolling. The stated aim is to confirm a lack of negative health effects from frequent plasmapheresis.

WHAT THE CORE STUDY PLANS TO DO

• Pilot: 50 to 90 donors at 2 centers, followed for 3 months.
• Main cohort: About 2,090 people, ages 18 to 74, followed for up to 2 years.
• Blood markers: Periodic whole-blood draws for CRP, ferritin, and IgG, plus surveys and illness reports.
• Clock: Primary completion aimed at July 1, 2028, with study completion listed into 2029.

Until those markers exist, the FDA limit is a rule, not a finished safety file. Watts’s own method is to look up the risks, talk to regulars, then stop reading. “You kind of go, ‘Oh, I don’t need to know that,’” he said. “I need this, so I’ll put the serious complications on the back burner.”

Why Unpaid Systems Still Buy U.S. Plasma

The World Health Organization’s goal, rooted in a 1975 World Health Assembly resolution, is for countries to obtain blood from voluntary unpaid donors. That rule still shapes Europe, the United Kingdom, Australia, and much of Canada. It has not produced enough plasma for immunoglobulin. Jaworski’s line on the cookies-and-milk boast is that those snacks cover about 44% of what those systems need. The rest comes from paid Americans.

His April 16, 2026 brief to Canada’s House of Commons health committee put numbers on that dependence. By July 2025, Canada collected only 27 to 28% of the plasma needed for immunoglobulin. It gathered enough source and recovered plasma for 3.1 million grams and imported 8.1 million grams from the United States, against 11.2 million grams of demand. Canadian demand rose from 6.2 million grams in 2015 to 11.2 million in 2025, about 6.1% a year, a path that reaches 20.3 million grams by 2035 if it holds. For every ten donors those patients depend on, he wrote, three are Canadian and seven are American.

WHO COLLECTS ENOUGH, AND WHO IMPORTS

The European Union as a whole is still nearly 40% dependent on plasma collected in the United States. The four EU countries that allow a flat fee are the ones that clear their own need. Everywhere else in that bloc is buying the difference. A 2025 analysis in Annals of Blood put immunoglobulin use in low- and middle-income countries at about 10 grams per 1,000 people, against about 200 grams in the United States. Latin America, the Middle East, and Africa together have accounted for about 1% of global plasma. Patients in those markets wait on a supply that starts in American strip-mall chairs, then moves through a 7-to-12-month manufacturing cycle before a vial shows up.

Jaworski wants other governments to copy the paid model rather than lecture it. He notes that when a U.S. plasma center opened near a blood bank, unpaid whole-blood donations ticked slightly up, not down. Bioethicists and public blood operators still disagree with him. The import invoices keep arriving either way.

Watts Still Arrives Before the Doors Open

Around the time Watts lost the UPS path, he and his partner split. She left the city with their child. In March 2026 he found part-time bakery work and moved from his car into a spare room at a friend’s house. He is still looking for better pay and still keeps the early slot twice a week. He has told his parents, a few friends, and one colleague. The colleague’s first reaction was disbelief.

Shame is part of the wage. So is the knowledge that the product works. Watts’s grandmother survived blood cancer about a decade ago, and plasma-derived treatment was part of that story. He tries to hold onto that when the rate is $40 and the needle is in. Colin, 20, in San Jose, compared the clinic with clinical drug trials and chose export over injection because it paid more and showed up every week. Sal, 35, in Houston, a veteran who once pawned his uniform, downs iron pills to pass vitals so he is not sent home.

The hour in the recliner is not the vacation in the ads. People leave tired, sometimes bruised, often calculating the next 48 hours against a bill. They also leave with a card that already spends. Until other countries collect their own volume, or until CORE actually reports IgG and ferritin on thousands of repeat donors, that trade is the system. Watts will be there when the doors open.

Disclaimer: This article is news reporting and analysis of paid plasma donation and the global trade in plasma-derived medicines. It is for information only and is not medical advice, a recommendation to donate or to stop donating, or financial advice. Anyone considering plasma donation should talk with a qualified physician about iron stores, immune status, medications, and donation frequency, and should read the consent forms at the collection center. Pay rates, center locations, study enrollment, and clinical guidance change, and the figures here reflect the company pages, research papers, and interviews cited.